News

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...
In Danes over age 65, the vaccine effectiveness of the JN.1-based mRNA boosters reached 70-85% against COVID-related ...
The primary efficacy was to demonstrate the vaccine efficacy against COVID-19 starting 14 days after mNEXSPIKE compared with Spikevax, Moderna's updated COVID-19 vaccine approved on Sept. 6, ...
Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual ...
Moderna Inc. (NASDAQ: MRNA) has announced plans to reduce its global workforce by approximately 10% by the end of the year ...
The U.S. Food and Drug Administration has granted full approval for Moderna's MRNA.O COVID-19 vaccine, Spikevax, in children ...
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
Moderna’s second-quarter sales fell less sharply than Wall Street expected as it works to expand its offerings amid weakening ...
Perhaps the most critical aspect of Moderna's business to pay attention to right now is its late-stage pipeline. The company ...